Abstract
Insulin resistance and obesity are intimately related to a chronic low grade systemic inflammation. Interleukin- 6 (IL-6) may influence the pathogenesis of obesity-related diseases. The aim of this study is to investigate the effect of bodys fat mass on the relationships between -174G/C IL-6 promoter gene polymorphism, IL-6 circulating level and insulin resistance. A population of 150 Caucasian women was studied, subdivided according to their body composition in non-obese (NW), Normal Weight Obese (NWO) and preobese-obese (OB). The NWO subjects were found in an intermediate position between the NW and OB subjects in terms of body weight, fat mass percentage (FM%), abdominal FAT%, hs-CRP and plasma triglyceride level. Fasting plasma IL-6 concentration was positively correlated with the homeostasis model assessment for insulin resistance (HOMA-IR) in all subjects analyzed (P=0.0014). In NWO and OB women a significantly increased IL-6 mean value was observed compared with NW subjects. In G/G population, the IL-6 plasma level of NWO and OB was significantly higher with respect to NW. No significant differences of IL-6 concentrations were observed in the three groups carrying G/C genotype. NWO and OB women homozygous for the allele C have significantly lower value of IL-6 with respect to NW subjects. IL-6 concentration was positively correlated with FM% in G/G (R2=0.397, P < 0.001) and was negatively correlated in C/C (R2=0.459, P=0.002). No significant correlation was observed in G/C genotype (R2=0.041, P=0.173). In conclusion our study confirms that, at least in Italian Caucasian females, the FM% is a major determinant of an increase in IL-6 production and insulin resistance. -174 G/C IL-6 promoter polymorphism represents a marker which could help to identify, time in advance, “vulnerable” individuals at risk of age and obesity related diseases.
Keywords: IL-6 -174 G/C promoter polymorphism, obesity, insulin resistance, body composition, obesity related diseases
Current Pharmaceutical Design
Title: Body Composition and -174G/C Interleukin-6 Promoter Gene Polymorphism: Association with Progression of Insulin Resistance in Normal Weight Obese Syndrome
Volume: 14 Issue: 26
Author(s): L. Di Renzo, A. Bertoli, M. Bigioni, V. Del Gobbo, M. G. Premrov, V. Calabrese, N. Di Daniele and A. De Lorenzo
Affiliation:
Keywords: IL-6 -174 G/C promoter polymorphism, obesity, insulin resistance, body composition, obesity related diseases
Abstract: Insulin resistance and obesity are intimately related to a chronic low grade systemic inflammation. Interleukin- 6 (IL-6) may influence the pathogenesis of obesity-related diseases. The aim of this study is to investigate the effect of bodys fat mass on the relationships between -174G/C IL-6 promoter gene polymorphism, IL-6 circulating level and insulin resistance. A population of 150 Caucasian women was studied, subdivided according to their body composition in non-obese (NW), Normal Weight Obese (NWO) and preobese-obese (OB). The NWO subjects were found in an intermediate position between the NW and OB subjects in terms of body weight, fat mass percentage (FM%), abdominal FAT%, hs-CRP and plasma triglyceride level. Fasting plasma IL-6 concentration was positively correlated with the homeostasis model assessment for insulin resistance (HOMA-IR) in all subjects analyzed (P=0.0014). In NWO and OB women a significantly increased IL-6 mean value was observed compared with NW subjects. In G/G population, the IL-6 plasma level of NWO and OB was significantly higher with respect to NW. No significant differences of IL-6 concentrations were observed in the three groups carrying G/C genotype. NWO and OB women homozygous for the allele C have significantly lower value of IL-6 with respect to NW subjects. IL-6 concentration was positively correlated with FM% in G/G (R2=0.397, P < 0.001) and was negatively correlated in C/C (R2=0.459, P=0.002). No significant correlation was observed in G/C genotype (R2=0.041, P=0.173). In conclusion our study confirms that, at least in Italian Caucasian females, the FM% is a major determinant of an increase in IL-6 production and insulin resistance. -174 G/C IL-6 promoter polymorphism represents a marker which could help to identify, time in advance, “vulnerable” individuals at risk of age and obesity related diseases.
Export Options
About this article
Cite this article as:
Di Renzo L., Bertoli A., Bigioni M., Gobbo Del V., Premrov G. M., Calabrese V., Di Daniele N. and De Lorenzo A., Body Composition and -174G/C Interleukin-6 Promoter Gene Polymorphism: Association with Progression of Insulin Resistance in Normal Weight Obese Syndrome, Current Pharmaceutical Design 2008; 14 (26) . https://dx.doi.org/10.2174/138161208786264061
DOI https://dx.doi.org/10.2174/138161208786264061 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Stem Cells (Guest Editor: Anand Srivastava)]
Current Topics in Medicinal Chemistry Syphilis: An Epidemiological Review
Current Women`s Health Reviews Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements
Mini-Reviews in Medicinal Chemistry Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Current Problems, New Opportunities and Future Directions of Antiplatelet Therapy - Increasing Role of Novel Antiplatelet Agents in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss
Current Drug Therapy Postmenopausal Hypertension: Insights from Rat Models
Current Hypertension Reviews Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Platelet Hyperreactivity and Stent Thrombosis in Patients Undergoing Coronary Stenting
Current Vascular Pharmacology Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease
Current Drug Targets Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research